Growing number of pts undergo radiotherapy

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 19 No 12
Volume 19
Issue 12

The number of patients in the U.S. treated with radiation has increased at an average annual rate of about 7% between 2007 and 2009, according to the “2010 Radiation Therapy Market Summary Report” by IMV. Breast, prostate, and lung cancers continue to be the cancer types treated most frequently with radiation.

The number of patients in the U.S. treated with radiation has increased at an average annual rate of about 7% between 2007 and 2009, according to the “2010 Radiation Therapy Market Summary Report” by IMV. Breast, prostate, and lung cancers continue to be the cancer types treated most frequently with radiation.

An estimated 1.1 million patients were treated in 2009 with radiation at 2,170 radiation therapy locations in the U.S. Compared to 2007, this represents a 15% increase from just over 954,000 patients, the report stated.

Over one-third of the sites surveyed reported that they are planning to purchase external-beam therapy units in the next three years, according to the report. Also, of the treatment planning systems installed, over half of the hardware or server technology was upgraded between 2008 and 2009.

Recent Videos
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
In a CancerNetwork® YouTube video, Cornelia Tischmacher, a mother of twins from Germany, outlined her receipt of double lung transplantation.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Related Content